Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Carryover effects”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources
PubMed1985

Coarticulation in Italian /VtV/ sequences: a palatographic study.

Patterns of linguopalatal contact during the production of intervocalic /t/ in different vowel contexts were examined by means of electropalatography, in order to assess the degree of dependency between tongue tip/blade and tongue body, the relative strength of anticipatory and carryover effects and their temporal extent. Results show that the coupling between tip and body of the tongue is rather loose: constraints imposed on tongue body by consonant production are described qualitatively and quantitatively. Carryover effects are stronger and more systematic than anticipatory effects: both can extend across the consonant. Results also indicate that coarticulatory effects depend on the identity of the vowel held constant and, to a lesser extent, on stress position. Some hypotheses are presented concerning articulatory goals and strategies in /VtV/ productions.

Biomechanical Phenomena↗
PubMed1997

Effects of ozone on normal and potentially sensitive human subjects. Part III: Mediators of inflammation in bronchoalveolar lavage fluid from nonsmokers, smokers, and asthmatic subjects exposed to ozone: a collaborative study.

To provide bases of comparison between the studies described in Parts I and II of this Research Report, concentrations of interleukin 6 (IL-6)*, interleukin 8 (IL-8), and alpha 2-macroglobulin (a2M) were measured in airway lavage fluids obtained in the Balmes study (Part I) and compared with the same measurements in the Frampton study (Part II). For healthy subjects in the Balmes study, IL-6 and a2M, but not IL-8, increased in association with ozone exposure. Statistical analyses suggested that effects of ozone on IL-8 levels observed in the first exposure and bronchoscopy may have carried over to the second exposure and bronchoscopy, which may have obscured an effect of ozone on IL-8 after the second exposure. For asthmatic subjects in the Balmes study, IL-6 and IL-8 increased in both bronchial and alveolar lavage fluid, but not in proximal airway lavage fluid. The mean interval between exposures was longer for asthmatic subjects than for healthy subjects, and no carryover effects were seen. When the Balmes and Frampton data were analyzed together, subject groups in the two studies (nonsmokers, smokers, and subjects without and with asthma) did not differ significantly in the response of cytokines to ozone exposure. The finding of possible carryover effects in one group suggests that subtle effects of ozone exposure, or bronchoscopy including proximal airway lavage and biopsy, or both, may persist for three weeks in some subjects.

Adolescent↗
PubMed2003

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.

We assessed the safety and efficacy of modafinil for the treatment of excessive daytime sleepiness in patients with Parkinson's disease (PD). This was a single-site, randomized, double-blind, placebo-controlled crossover study of 21 PD patients having an Epworth Sleepiness Scale (ESS) score > or =10. They received either placebo or modafinil 200 mg/day for 3 weeks, followed by a washout week, then the alternate treatment for 3 weeks. The ESS data demonstrated a carryover effect, so the changes from baseline ESS scores were compared between the two treatments for period 1 only. The ESS scores for the placebo group went from 16.0 +/- 4.2 (mean +/- SD) to 17.0 +/- 5.1 and for the modafinil group went from 17.8 +/- 4.2 to 14.4 +/- 5.7 (P = 0.039). There was no significant carryover effect for any other measure. The patient Clinical Global Impression of Change (+3 to -3) improved by 0.75 on modafinil compared with 0.15 for placebo (P = 0.07). A total of 7 of 20 (35%) of the patients reported some improvement on modafinil but not placebo. There was no significant improvement or worsening of the UPDRS subscores I-III, Timed Tap test, or time on. Vital signs, electrocardiograms, and lab tests were unchanged. Modafinil was very well tolerated. Our data demonstrate that, in a small sample size, administration of 200 mg/day of modafinil was associated with few side effects and was modestly effective for the treatment of excessive daytime sleepiness in patients with PD.

Adult↗
PubMed1992

Crossover design in pharmacy research.

OBJECTIVE: Reports of pharmacy research using crossover designs were reviewed to determine if the studies adequately consider interaction effects and use appropriate statistical analyses. DATA SOURCES: All crossover studies published in DICP, The Annals of Pharmacotherapy during 1988 and 1989 were analyzed. STUDY SELECTION: Reports of crossover studies were included only if at least two treatments were applied in a different order to two or more groups of subjects. DATA EXTRACTION: The principal characteristics of crossover studies and the critical design variables were listed and each study analyzed according to these variables. The critical design variables included consideration of period, sequence, and carryover effects as well as the presentation of data by groups and the use of multivariate statistical analysis. The analysis was conducted independently by each author and conflicts were discussed until consensus was obtained. RESULTS: A total of 11 crossover studies were identified: 6 were bioavailability trials, 3 were treatment comparisons, and 2 had multiple objectives. The possibility of period, sequence, or carryover effects was less with bioavailability studies than with treatment comparisons. Only 1 study presented data by group and only 4 studies used multivariate analysis. CONCLUSIONS: The crossover design appears more appropriate for bioavailability trials than for treatment trials in pharmacy research. Analysis of data from crossover designs could be improved by presenting the data for each treatment group and using multivariate statistical analysis.

Analysis of Variance↗
PubMed1995

Pediatric adenoidal hypertrophy and nasal airway obstruction: reduction with aqueous nasal beclomethasone.

OBJECTIVE: Pediatric adenoidal obstruction of the nasal airway is associated with significant morbidity and is a frequent indication for surgery. Because efficacious medical alternatives to adenoidectomy are lacking, we assessed the potency of standard-dose topical nasal beclomethasone in reduction of adenoidal obstruction of the nasal airway. METHODS: Seventeen children, 5 to 11 years of age, exhibiting chronic obstructive nasal symptoms and a group mean (+/- SE) adenoid/choana ratio of 91 +/- 1% on rhinoscopic examination, completed an 8-week, double-blind, placebo-controlled crossover study of standard-dose aqueous nasal beclomethasone (total 336 micrograms/day) in the treatment of adenoidal hypertrophy. In a 16-week, open-label, follow-on study, subjects received beclomethasone 1 spray in each nostril twice daily (168 micrograms/day). RESULTS: Over the initial 4 weeks, improvements in the mean adenoidal obstruction of the choanae were significantly greater in the group receiving beclomethasone than in the group receiving placebo (right, -14.0% vs. +0.4%, P = .0002) (left, -15.0% vs. -2.0%, P = .0006). In the subsequent crossover 4 weeks, a significant beclomethasone carryover effect resulted in further adenoid size reduction in both treatment groups. All patients demonstrated a decrease in adenoid size with beclomethasone treatment, compared with a mixed response to placebo. Over the full 8-week crossover study, the mean (+/- SE) obstructive symptom score after beclomethasone treatment (20.5 +/- 3.0) was significantly improved compared to patients' initial (43.1 +/- 2.9) and placebo scores (31.1 +/- 4.2, P < or = .05), despite the active drug carryover effect into the placebo treatment period. Significant improvements in adenoidal obstruction and symptom scores over the 8-week crossover study were enhanced in the subsequent 16-week open-label period (P = .0001). By 24 weeks, an 82% reduction in group mean nasal obstruction symptom score accompanied a 29% mean reduction in adenoid/choana ratio. No clinical or demographic characteristic predicted a patient's degree of response to treatment. CONCLUSIONS: Properly administered aqueous nasal beclomethasone in standard doses can significantly reduce adenoidal hypertrophy and nasal airway obstructive symptoms in children.

Adenoids↗
PubMed2000

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia.

Experimental and clinical data suggest that GABA-ergic drugs such as valproate may have a potential role in the treatment of schizophrenia. The authors designed a 21-day prospective, double-blind, randomized, placebo-controlled pilot study of divalproex sodium as add-on treatment to haloperidol in 12 hospitalized patients with acute exacerbations of chronic schizophrenia. All patients received haloperidol 10 mg/day for 3 days and 15 mg/day for the remaining 18 days. In addition, five patients were randomly assigned to receive divalproex augmentation and seven to receive placebo. The divalproex dose was adjusted to a target serum concentration of 75 microg/mL for 2 weeks; placebo replaced divalproex during the third and last weeks to determine any carryover effect. Psychiatric rating scales were administered at baseline and on days 7, 14, and 21. Although the placebo group improved with haloperidol treatment, the divalproex group demonstrated greater improvement. On day 21, the divalproex group had greater improvement from baseline on the Clinical Global Impression Scale (p < or = 0.04), Brief Psychiatric Rating Scale (p < or = 0.13), and Schedule for Assessment of Negative Symptoms scores (p < or = 0.007). After divalproex withdrawal on day 15, a carryover effect was observed during week 3. The authors concluded that the addition of divalproex sodium to standard antipsychotic drugs may prove effective in relieving the symptoms of acute schizophrenia. Future studies may benefit from the design of this pilot study. However, it is premature to apply this augmentation strategy in the clinical setting just yet because of the small sample size and the likely heterogeneity of the disorder.

Acute Disease↗
PubMed1990

Serum gentamicin assay: an assessment of two different Syva EMIT and Abbot TDx instruments.

The accuracy and reproducibility of two different Syva EMIT and Abbot TDx instruments for the determination of gentamicin were assessed. A series of spiked standard serum samples containing gentamicin in concentrations ranging from 0.88-17.82 mg/l were used for this purpose. Both TDx systems evaluated had excellent reproducibility but overestimated gentamicin levels in the clinically important concentration range in an apparent concentration-dependent way by at least 5 and 10%, respectively. In addition both these systems exhibited considerable carryover effects when high concentration gentamicin samples (17.82 mg/l) were alternated with serum blanks. Average gentamicin levels determined by the EMIT systems were much closer to the target values, especially those of EMIT-A, than those measured by the TDx-systems. The reproducibility, as measured by the coefficient of variation (CV), of the semi-automated EMIT systems over the entire concentration range investigated was about half that of the TDx-systems. No carryover effects were observed with the two EMIT-systems. This study has shown that the accuracy and reproducibility of both assay methods vary considerably over the clinically important gentamicin concentration range. In addition there may be a large variation between instruments of the same system especially in the critical trough region for gentamicin.

Fluorescence Polarization↗
PubMed2001

High-dose intravenous immune globulin for stiff-person syndrome.

BACKGROUND: Stiff-person syndrome is a disabling central nervous system disorder with no satisfactory treatment that is characterized by muscle rigidity, episodic muscle spasms, high titers of antibodies against glutamic acid decarboxylase (GAD65), and a frequent association with autoimmune disorders. Because stiff-person syndrome is most likely immune-mediated, we evaluated the efficacy of intravenous immune globulin. METHODS: We assigned 16 patients who had stiff-person syndrome and anti-GAD65 antibodies, in random order, to receive intravenous immune globulin or placebo for three months, followed by a one-month washout period and then by three months of therapy with the alternative agent. Efficacy was judged by improvements in scores on the distribution-of-stiffness index and heightened-sensitivity scale from base line (month 1) to the second and third month of each treatment phase. Direct and carryover effects of treatment were compared in the two groups. RESULTS: Among patients who received immune globulin first, stiffness scores decreased significantly (P=0.02) and heightened-sensitivity scores decreased substantially during immune globulin therapy but rebounded during placebo administration. In contrast, the scores in the group that received placebo first remained constant during placebo administration but dropped significantly during immune globulin therapy (P=0.01). When the data were analyzed for a direct and a first-order carryover effect, there was a significant difference in stiffness scores (P=0.01 and P<0.001, respectively) between the immune globulin and placebo groups, and immune globulin therapy had a significant direct treatment effect on sensitivity scores (P=0.03). Eleven patients who received immune globulin became able to walk more easily or without assistance, their frequency of falls decreased, and they were able to perform work-related or household tasks. The duration of the beneficial effects of immune globulin varied from six weeks to one year. Anti-GAD65 antibody titers declined after immune globulin therapy but not after placebo administration. CONCLUSIONS: Intravenous immune globulin is a well-tolerated and effective, albeit costly, therapy for patients with stiff-person syndrome and anti-GAD65 antibodies.

Adult↗
PubMed2006

A detailed study of thermal decomposition, amalgamation/ atomic absorption spectrophotometry methodology for the quantitative analysis of mercury in fish and hair.

The analytical method for determining the concentration of mercury in fish by thermal decomposition, amalgamation/ atomic absorption spectrophotometry was thoroughly studied. Specific issues addressed were accurate modeling of instrumental response, the use of quartz and nickel boats, carryover effects, software limitations, and troubleshooting. The DMA-80 Direct Mercury Analyzer instrument was calibrated using a total of 22 points, and the resultant curves statistically analyzed. At minimum, second-order polynomials were required to adequately model the data. TORT-2 standard reference material was analyzed in both quartz and nickel boats and found to give equivalent performance in both types of vessels and well within the 95% confidence interval. DOLT-3 standard reference material also yielded values well within the 95% confidence interval, but the DORM-2 standard reference material did not. Carryover effects were found to be minimal with a new catalyst tube but increased with catalyst age. Blanks should be run after the analysis of high mercury content samples; however, when the catalyst has aged, two blanks are required to reduce apparent mercury signals to nominal blank values. Comparable results between thermal decomposition, amalgamation/atomic absorption spectrophotometry and cold-vapor atomic absorption spectrophotometry were demonstrated. The feasibility of using this instrument to analyze hair was also explored and found to be suitable. Software problems and limitations have been noted when attempting to implement a high-throughput methodology. Instrumental drift was found to be minimal when operated over long periods. Blank values can provide important diagnostic indicators.

Animals↗
PubMed2007

Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy.

BACKGROUND: Oral mucositis (OM) is a frequent complication of mucotoxic cancer therapy, causing significant oral pain, increased infection risk, and impaired functioning. The efficacy and safety of Saforis (glutamine) powder in UpTec for oral suspension was evaluated for the prevention and treatment of OM. METHODS: Three hundred twenty-six patients developing World Health Organization (WHO) grade >or=2 OM during a chemotherapy screening cycle were randomized to Saforis (n = 163) or placebo (n = 163) 3 times/day during their next chemotherapy cycle (Treatment Cycle 1). Patients were crossed over to the alternate treatment during Treatment Cycle 2. As prespecified in the statistical plan, because of a carryover effect in Treatment Cycle 2 the primary efficacy analysis was based on Treatment Cycle 1 only. RESULTS: Compared with placebo, Saforis significantly reduced the incidence of clinically significant WHO grade >or=2 OM (38.7% vs. 49.7%; P = .026) and severe WHO grade >or=3 OM (1.2% vs. 6.7%; P = .005) in Treatment Cycle 1. Saforis also significantly reduced the worst Oral Mucositis Assessment Scale ulceration score in Treatment Cycle 1 compared with placebo (mean, 0.23 +/- 0.39 vs. 0.32 +/- 0.45; P = .013). Patients receiving Saforis in Treatment Cycle 1 had a lower-than-expected OM incidence when crossed over to placebo in Treatment Cycle 2, indicating a significant carryover effect (P = .027). The incidence of treatment-emergent adverse events was similar between groups. CONCLUSIONS: Saforis is safe and effective for preventing and treating OM in patients receiving mucotoxic cancer chemotherapy.

Adult↗
PubMed1999

Failure to confirm the Rauscher and Shaw description of recovery of the Mozart effect.

The Mozart effect is an increase in spatial reasoning scores detected immediately after listening to the first movement of a Mozart piano sonata. Rauscher and Shaw (1998) suggested that failure to produce a Mozart effect could arise from carryover effects of a spatial reasoning pretest which may interfere with the effect of listening to Mozart. They cited an unpublished study in which a verbal distractor was inserted between the pretest and listening condition, and the manipulation produced the recovery of a Mozart effect. This experiment attempted to confirm the unpublished study. 206 college students were exposed to one of three sequences, pretest-Verbal distractor material-Mozart, pretest-Mozart-Verbal distractor material, and pretest-Verbal distractor material. An immediate posttest indicated no significant difference on solution of paper folding and cutting items among the three groups. The results do not support Rauscher and Shaw (1998). Our negative results are consistent with prior failures in other laboratories to produce a Mozart effect.

Attention↗
PubMed1990

Caffeine preexposure sensitizes rats to the motor activating effects of cocaine.

Rats were preexposed to caffeine or to water vehicle with nine daily injections (20 mg/kg, i.p.). On each of the 9 days, the motor activating response to the drug was assessed in open field boxes. On the tenth day, water and caffeine preexposed rats were challenged with a single injection of cocaine HCI (10 mg/kg, i.p.) or vehicle, and the activational effect of cocaine was assessed. The rats that had been pretreated with caffeine showed a larger response to cocaine than their vehicle treated counterparts, suggesting that caffeine exposure enhanced the response to cocaine. Since caffeine-preexposed rats responded to the vehicle injection on test day in much the same manner as rats that had received chronic injections of the water vehicle, it is unlikely that the increase in cocaine effect was due to carryover effects of the caffeine pretreatment or conditioned activity due to the preexposure. These data add to the literature base describing predisposing factors in cocaine sensitivity, and suggest that readily available stimulants, like caffeine, may serve to prime central systems that mediate the response to cocaine.

Journal Article↗
PubMed2003

Evaluation of CO exposure in active smokers while smoking using breath analysis technique.

The current study evaluated the personal CO exposure of active smokers while smoking under controlled conditions, decay rate of CO in the body following active smoking, and CO accumulation in the body from repeated active smoking using a novel device for the direct measurement of alveolar breath CO. Prior to this evaluation, the proposed alveolar CO measurement device was successfully evaluated as regards the effect of humidity, CO recovery, carryover effect, and in comparison with the bag sampling method. The breath concentrations prior to and after a single cigarette were measured using a repeated measure design. Under the controlled conditions employed in the present study, active smoking was found to cause a significant body burden of CO. The post-exposure breath CO level was 1.6-2.0 times higher than the background breath level, depending on the subject and cigarette brand. In addition, the pre- and post-exposure breath concentrations were both significantly different among the subjects, yet the ratios of post-exposure to pre-exposure breath concentrations did not differ significantly between the different cigarette brands. The time-series alveolar breath concentrations measured following active smoking showed that the post-exposure alveolar CO concentrations decreased slowly even in the early phase of the decay curves, indicating a mono-compartment uptake and elimination model for the human body. The half-lives estimated in the present study (301, 315, and 385 min) were longer than or comparable to those in previous studies. The breath measurements prior to and after repeated active smoking exhibited a significant increasing trend for both the pre- and post-exposure concentrations. The changes in the pre- and post-exposure breath CO concentrations with repeated smoking ranged from 7% to 23% and from 10% to 15%, respectively, with half-hour intervals between cigarettes, and from 4% to 11% and from 6% to 8%, respectively, with hour intervals between cigarettes. Accordingly, most of the current results indicated that CO was accumulated in the human body with repeated active smoking.

Adult↗
PubMed2005

Intraarticular hyaluronic acid versus glucocorticoid injections for nonradicular pain in the lumbar spine.

PURPOSE: To investigate the efficacy and safety of intraarticular sodium hyaluronate (SH) compared with intraarticular glucocorticoids (triamcinolone acetonide; TA) in the treatment of chronic nonradicular lumbar pain. MATERIALS AND METHODS: Sixty patients were included in this randomized, controlled, blind-observer clinical study and randomly assigned to two groups to receive 10 mg SH or 10 mg TA per facet joint. The facet joints on both sides at levels S1-L5, L5-L4, and L4-L3 were treated once per week under computed tomographic guidance. The study visits were timed to permit assessment of the immediate effect as well as possible carryover effects at 3 and 6 months after completion of treatment. Changes in pain were assessed with a visual analog scale (VAS) and changes in function and quality of life were assessed by the Roland Morris Questionnaire (RMQ), the Oswestry Disability Questionnaire (ODQ), the Low Back Outcome Score (LBOS), and the Short Form 36 (SF-36) questionnaire. RESULTS: Patients reported lasting pain relief, better function, and improved quality of life with both treatments. Mann-Whitney analyses of the patient questionnaires (RMQ, ODQ, and LBOS) very consistently showed that SH is not inferior to TA. In addition, the efficacy of SH was largely comparable with that of TA on the VAS and SF-36. No adverse effects were reported after administration of the test products. The intraarticular treatment of facet joints (levels S1-L5, L5-L4, and L4-L3) with SH in patients with chronic nonradicular pain in the lumbar spine resulted in a marked reduction in pain with improved function and better quality of life, which was at least equal to the effect of a course of TA injections. SH-treated patients showed greater benefits in the long term. CONCLUSION: Intraarticular SH is a very promising new option for the treatment of patients with chronic nonradicular lumbar symptoms.

Adjuvants, Immunologic↗
PubMed1990

Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs.

In studying patients with mild hypertension, we used a double-blind, randomly allocated crossover, 2 x 2 factorial design to obtain more precise estimates of the effectiveness of individual hypertensive drugs and of the interactions when used in combination. In the present study, we reanalysed data from our own previously completed crossover factorial studies in order to determine the optimal length of phases and to try to exploit patient heterogeneity by comparing blood pressure responses within each patient to the two different drugs in each study. An analysis of the 'weeks within phases' variation (analysis of variance) applied to all phases, to the placebo phases alone and to the active treatment phases alone, of the individual factorial studies and of pooled data from studies of similar design, only revealed differences in the first week of our 4-week phases. Accordingly, we suggest that 4 weeks is an optimal phase length, since only the values from the third and fourth weeks showed the full expression of a drug's antihypertensive effect, avoiding the problem of a carryover effect and the need for a more complex intervening washout placebo phase. Comparing the blood pressure reductions shown by individual patients in response to different antihypertensive drugs using arbitrary criteria of greater than or equal to 5, 10 and 15 mmHg for diastolic and greater than or equal to 5, 10 and 20 mmHg for systolic pressure, we were unable to distinguish between the two separate drugs in each factorial study, due to the magnitude of the background variation which had a coefficient of variation of 5-7%.(ABSTRACT TRUNCATED AT 250 WORDS)

Antihypertensive Agents↗
PubMed1994

The importance of placebo effects in pain treatment and research.

OBJECTIVE: To estimate the importance and implications of placebo effects in pain treatment and research from the existing literature, with emphasis on their magnitude and duration, the conditions influencing them, and proposed explanations. DATA SOURCES: English-language articles and books identified through MEDLINE (1980 through 1993) and PsycLIT (1967 through 1993) database searching, bibliography review, and expert consultation. STUDY SELECTION: Articles were included if they pertained to the review objectives. RESULTS: Placebo response rates vary greatly and are frequently much higher than the often-cited one third. Placebos have time-effect curves, and peak, cumulative, and carryover effects similar to those of active medications. As with medication, surgery can produce substantial placebo effects, and this possibility is commonly overlooked in case series reports on back surgery. Individuals are not consistent in their placebo responses, and a placebo-responder personality has not been identified. Models advanced to explain placebo effects emphasize the role of anxiety, expectations, and learning. CONCLUSIONS: Placebo effects influence patient outcomes after any treatment, including surgery, that the clinician and patient believe is effective. Placebo effects plus disease natural history and regression to the mean can result in high rates of good outcomes, which may be misattributed to specific treatment effects. The true causes of improvements in pain after treatment remain unknown in the absence of independently evaluated randomized controlled trials.

Dose-Response Relationship, Drug↗
PubMed1984

A double-blind clinical trial of hydroxyethylrutosides in Menière's disease.

A double-blind, placebo-controlled, cross-over trial was undertaken in 39 patients with well-defined Menière's disease. After a one-month placebo run-in period, the patients were assigned, on a randomized basis, to three months' treatment with O-(beta-hydroxyethyl)-rutosides (HR) (2 g./day) followed by three months on placebo, or vice-versa. In spite of a very pronounced placebo effect and a marked tendency to a 'carryover' effect from the first sequence with HR into the second placebo sequence, there appeared to be a clear trend to a greater symptomatic improvement with HR treatment than with placebo. The audiometric findings showed a very clear, uniform superiority under HR treatment, for both air and bone conduction and at all five frequencies studied (250, 500, 1,000, 2,000 and 5,000 Hz.) (p values between 0.002 and 0.05). Indeed, whereas there was a worsening of hearing-loss at each frequency under placebo during the first sequence, this was significantly diminished at each frequency under HR treatment. There were no significant changes in vestibulometry (caloric test) which showed wide variations already during the run-in period. Tolerance to HR treatment was excellent, the incidence of side-effects being similar to that in the placebo periods.

Adult↗
PubMed1986

Analytical performance of the random access analyser Hitachi 737. A multicentre evaluation.

The selective multitest analyser Hitachi 737 was examined according to the ECCLS guidelines in a multicentre evaluation involving 4 laboratories. Twenty routine parameters, including the electrolytes, sodium, potassium and chloride, were measured at 37 degrees C. All of the measured values were included for evaluation without correcting for outliers. The trial, which lasted 4 months and involved over 70 000 analyses, basically yielded the following results: The precision can be termed very good. For the majority of the methods, the day-to-day coefficients of variation were below 2%. The highest coefficient of variation was 6.3% (for creatine kinase) and the lowest below 0.1% (for gamma-glutamyltransferase). The recovery of the assigned values of control sera was very good for most of the parameters (between 95% and 105%). Only with bilirubin, phosphate and chloride did greater deviations occur in a few control sera. Excellent agreement was found between the results obtained from the instruments used in the comparison: the Hitachi 705, a flame photometer and a chloride meter. No drift effects were observed. The same applied to carryover effects, provided that Boehringer Mannheim's recommendations concerning method combinations are observed. Because of the large measuring range, it is necessary to repeat analyses only in exceptional cases. During the entire period of the trial there were no stoppages due to the instrument malfunction. As a result of its reliability, the Hitachi 737 is well suited for routine operation and emergency analysis in medium to large-sized laboratories.

Autoanalysis↗